FI118676B - Menetelmä kohdentamisryhmän ja 213Bi-radioisotoopin konjugaatin valmistamiseksi - Google Patents

Menetelmä kohdentamisryhmän ja 213Bi-radioisotoopin konjugaatin valmistamiseksi Download PDF

Info

Publication number
FI118676B
FI118676B FI933350A FI933350A FI118676B FI 118676 B FI118676 B FI 118676B FI 933350 A FI933350 A FI 933350A FI 933350 A FI933350 A FI 933350A FI 118676 B FI118676 B FI 118676B
Authority
FI
Finland
Prior art keywords
conjugate
antigen
isotope
targeting
antibody
Prior art date
Application number
FI933350A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI933350A (fi
FI933350A0 (fi
Inventor
Maurits Willem Geerlings
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI933350A0 publication Critical patent/FI933350A0/fi
Publication of FI933350A publication Critical patent/FI933350A/fi
Application granted granted Critical
Publication of FI118676B publication Critical patent/FI118676B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G4/00—Radioactive sources
    • G21G4/04—Radioactive sources other than neutron sources
    • G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
    • G21G4/08—Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Tents Or Canopies (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Massaging Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrotherapy Devices (AREA)
FI933350A 1992-07-27 1993-07-26 Menetelmä kohdentamisryhmän ja 213Bi-radioisotoopin konjugaatin valmistamiseksi FI118676B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP92202301 1992-07-27
EP92202301 1992-07-27
EP93200388 1993-02-11
EP93200388 1993-02-11

Publications (3)

Publication Number Publication Date
FI933350A0 FI933350A0 (fi) 1993-07-26
FI933350A FI933350A (fi) 1994-01-28
FI118676B true FI118676B (fi) 2008-02-15

Family

ID=26131590

Family Applications (1)

Application Number Title Priority Date Filing Date
FI933350A FI118676B (fi) 1992-07-27 1993-07-26 Menetelmä kohdentamisryhmän ja 213Bi-radioisotoopin konjugaatin valmistamiseksi

Country Status (15)

Country Link
US (2) US5641471C1 (de)
EP (1) EP0585986B1 (de)
JP (1) JP3959431B2 (de)
KR (1) KR100304155B1 (de)
AT (1) ATE206622T1 (de)
AU (1) AU676162B2 (de)
CA (1) CA2100709C (de)
DE (1) DE69330899T2 (de)
DK (1) DK0585986T3 (de)
ES (1) ES2165361T3 (de)
FI (1) FI118676B (de)
MX (1) MX9304499A (de)
NO (1) NO312009B1 (de)
NZ (1) NZ248235A (de)
PT (1) PT585986E (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
ATE223237T1 (de) * 1996-11-15 2002-09-15 Euratom Ex-corpore verfahren zur behändlung von blut- zellen
US5749042A (en) * 1997-01-28 1998-05-05 Battelle Memorial Institute Bismuth generator method
US5854968A (en) * 1997-06-09 1998-12-29 Arch Development Corporation Process and apparatus for the production of BI-213 cations
US6603127B1 (en) * 1998-03-30 2003-08-05 Sloan-Kettering Institute For Cancer Research Bismuth-213 generator and uses thereof
US7736651B1 (en) 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
ES2299256T3 (es) * 1998-05-26 2008-05-16 Sloan-Kettering Institute For Cancer Research Constructos que emiten particulas alfa y sus usos.
ES2203856T3 (es) * 1998-06-22 2004-04-16 European Community Metodo y aparato para la preparacion de bi-213 para uso terapeutico humano.
EP1187637A2 (de) * 1999-06-07 2002-03-20 Center For Molecular Medicine And Immunology Alpha und beta strahlern angekoppelt zu fragmente im radioimmunotherapie
US6852296B2 (en) * 2001-06-22 2005-02-08 Pg Research Foundation Production of ultrapure bismuth-213 for use in therapeutic nuclear medicine
US7087206B2 (en) * 2002-04-12 2006-08-08 Pg Research Foundation Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine
US7211231B2 (en) 2002-06-21 2007-05-01 Lynntech, Inc. Ion exchange materials for use in a 213Bi generator
EP1479399A1 (de) * 2003-05-22 2004-11-24 European Atomic Energy Community (Euratom) Verfahren zum Beladen eines Radioelementerzeugers mit einem Mutternuklid
US20050105666A1 (en) * 2003-09-15 2005-05-19 Saed Mirzadeh Production of thorium-229
EP2456472B1 (de) 2009-07-22 2024-03-27 Actinium Pharmaceuticals, Inc. Verfahren zur erzeugung von radioimmunkonjugaten
CA2987628A1 (en) 2015-06-05 2016-12-08 Panacea Pharmaceuticals Inc. Radio-imaging and radio-therapy of cancer using antibodies to haah
EP3409297A1 (de) 2017-05-30 2018-12-05 AlfaRim Medial Holding B.V. Optimaler 225actinium-213bismut-generator für alpha-partikelradioimmunotherapie
US20200230266A1 (en) 2017-09-20 2020-07-23 Alfarim Medical Holding B.V. The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001387A (en) * 1973-07-30 1977-01-04 Medi-Physics, Inc. Process for preparing radiopharmaceuticals
US4305922A (en) * 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4296785A (en) * 1979-07-09 1981-10-27 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
CA1225930A (en) * 1982-06-07 1987-08-25 Otto A. Gansow Metal chelate conjugated monoclonal antibodies
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4663129A (en) * 1985-01-30 1987-05-05 The United States Of America As Represented By The United States Department Of Energy Isotopic generator for bismuth-212 and lead-212 from radium
IL87405A0 (en) * 1987-08-12 1989-01-31 Immunomedics Inc Radiolabeled agents and methods and kits for the production thereof
US4833329A (en) * 1987-11-20 1989-05-23 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4871352A (en) * 1987-12-07 1989-10-03 Controlled Release Technologies, Inc. Self-regulated therapeutic agent delivery system and method
WO1989011475A1 (en) * 1988-05-25 1989-11-30 The United States Of America, As Represented By Th Macrocyclic chelates and methods of use thereof
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
JPH089553B2 (ja) * 1989-06-19 1996-01-31 アクゾ・エヌ・ヴエー α粒子放出を使用する放射免疫療法
JP3194433B2 (ja) * 1989-07-12 2001-07-30 マリンクロッド・インコーポレイテッド 放射線診断用気体放射性核種の製造方法および放射線診断用気体放射性核種の製造装置
LU87684A1 (de) * 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5038046A (en) * 1990-07-10 1991-08-06 Biotechnetics Method and generator for producing radioactive lead-212
CA2100709C (en) * 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy

Also Published As

Publication number Publication date
NO312009B1 (no) 2002-03-04
PT585986E (pt) 2002-03-28
DK0585986T3 (da) 2002-01-14
NO932687D0 (no) 1993-07-26
KR100304155B1 (ko) 2001-11-22
DE69330899D1 (de) 2001-11-15
ATE206622T1 (de) 2001-10-15
JP3959431B2 (ja) 2007-08-15
NZ248235A (en) 1995-04-27
FI933350A (fi) 1994-01-28
MX9304499A (es) 1994-04-29
FI933350A0 (fi) 1993-07-26
DE69330899T2 (de) 2002-04-25
AU676162B2 (en) 1997-03-06
AU4215493A (en) 1994-02-03
JPH06157350A (ja) 1994-06-03
ES2165361T3 (es) 2002-03-16
CA2100709A1 (en) 1994-01-28
US5641471A (en) 1997-06-24
CA2100709C (en) 2004-03-16
EP0585986B1 (de) 2001-10-10
KR940005295A (ko) 1994-03-21
US5641471C1 (en) 2001-05-15
NO932687L (no) 1994-01-28
US6127527A (en) 2000-10-03
EP0585986A1 (de) 1994-03-09

Similar Documents

Publication Publication Date Title
FI118676B (fi) Menetelmä kohdentamisryhmän ja 213Bi-radioisotoopin konjugaatin valmistamiseksi
McDevitt et al. Preparation of α-emitting 213Bi-labeled antibody constructs for clinical use
Lindegren et al. Realizing clinical trials with astatine-211: the chemistry infrastructure
US20140235924A1 (en) Method of radiotherapy
Wilbur et al. Preparation and evaluation of para-[211At] astatobenzoyl labeled anti-renal cell carcinoma antibody A6H F (ab′) 2. In vivo distribution comparison with para-[125I] iodobenzoyl labeled A6H F (ab′) 2
Huclier-Markai et al. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics
US20080279772A1 (en) Methods for detecting pathological sites
US6603127B1 (en) Bismuth-213 generator and uses thereof
US20210130253A1 (en) Purification method
EP1617876B1 (de) Thorium-227 zur radiotherapie von weichgewebe-erkrankungen
JP2019509327A (ja) 同位体精製方法
Larsen et al. Intratumour injection of immunoglobulins labelled with the α-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay
Press Physics for practitioners: the use of radiolabeled monoclonal antibodies in B-cell non-Hodgkin's lymphoma
Vallabhajosula Radiopharmaceuticals for therapy
US20200230266A1 (en) The optimal 225actinium--213bismuth generator for alpha-particle radioimmunotherapy
EP0842668B1 (de) Ex-Corpore Verfahren zur Behändlung von Blut-Zellen
EP3409297A1 (de) Optimaler 225actinium-213bismut-generator für alpha-partikelradioimmunotherapie
McDevitt et al. Constructs for Clinical Use
Zimmer et al. Radiation Protection and Radiation Measurement Issues with Non-Traditional Radiopharmaceuticals
Lee et al. Biodistribution Property of 177 Lu Labeled F (ab’) 2 Fragment of Anti-CD105 for Radioimmunotherapy

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118676

Country of ref document: FI

MA Patent expired